CytomX Therapeutics Announces Second Quarter 2018 Financial Results
- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - - Preliminary Proof-of-Concept for Probody™ Platform and CX-072 - SOUTH SAN FRANCISCO, Calif …